LUNGEVITY FOUNDATION

A retrospective study suggests that less restrictive eligibility criteria in clinical trials for metastatic non-small cell lung cancer (NSCLC) could improve patient outcomes.

LUNGevity, FDA, and NCI are collaborating to standardize eligibility criteria for advanced non-small cell lung cancer (NSCLC) clinical trials, aiming to simplify trial navigation for patients.